Analyzing the Scope and Claims of United States Patent 10,287,586
Introduction
United States Patent 10,287,586, titled "Antisense molecules and methods for treating pathologies," is a significant patent in the field of genetic therapies, particularly for treating genetic diseases such as Duchenne muscular dystrophy. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Patent Overview
The patent, issued to a group of inventors, describes antisense molecules designed to bind to specific target sites in the dystrophin gene to induce exon skipping. This technique is crucial for treating genetic disorders caused by mutations in the dystrophin gene, such as Duchenne muscular dystrophy[4].
Scope of the Patent
The scope of a patent is defined by its claims, which outline the specific inventions and methods that are protected.
Independent Claims
The patent includes several independent claims that define the core of the invention. These claims typically describe the antisense molecules, their structure, and their method of use. For example:
- Claim 1: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene.
- Claim 10: A method for treating a patient suffering from a genetic disease, comprising administering an antisense molecule to the patient[4].
Dependent Claims
Dependent claims further specify the invention by adding additional limitations to the independent claims. These claims often detail specific aspects such as the composition of the antisense molecules, the target exons, and the methods of administration.
Claim Language and Patent Scope
The language used in the claims is critical in defining the patent's scope. Research has shown that the length and count of independent claims can be metrics for measuring patent scope. Narrower claims, as seen in this patent, are often associated with a higher probability of grant and a shorter examination process[3].
Target Sites and Exon Skipping
The patent focuses on antisense molecules that target specific exons in the dystrophin gene to induce exon skipping. This technique is aimed at bypassing mutations that cause genetic diseases. The target sites include exons 3, 4, 8, 10, 26, 36, 48, 60, 66, and 68, highlighting the precision and specificity of the invention[4].
Methods of Treatment
The patent describes methods for treating genetic diseases, including Duchenne muscular dystrophy, by administering the antisense molecules. These methods involve selecting appropriate antisense molecules and delivering them to patients in a form suitable for therapeutic use. The invention also includes prophylactic treatments to prevent or minimize the onset of Duchenne muscular dystrophy[4].
Pharmaceutical Compositions and Kits
The patent covers not only the antisense molecules but also pharmaceutical compositions and kits that include these molecules. These kits are packaged with instructions for use, making them ready for clinical application[4].
Patent Landscape
International Patents
The invention is protected not only in the United States but also through international patents. Databases such as the World Intellectual Property Organization (WIPO) PATENTSCOPE and the European Patent Office (EPO) esp@cenet provide access to these international patent filings, ensuring global protection for the invention[1].
Prior Art and Citation Data
The Common Citation Document (CCD) application consolidates prior art cited by participating IP offices, including the IP5 Offices. This helps in visualizing the search results for the same invention produced by several offices on a single page, ensuring that the patent is novel and non-obvious over existing prior art[1].
Expiration and Generic Entry
The patent's expiration date and potential generic entry are crucial for understanding its market impact. Websites like DrugPatentWatch provide detailed information on patent expiration dates and the potential for generic competition, which can affect the commercial viability of the patented invention[5].
Search and Examination Process
The patent underwent a rigorous examination process, which is evident from the changes in claim language and scope during the examination. Narrower claims at publication are associated with a higher probability of grant and a shorter examination process, as observed in this patent[3].
Global Dossier and Office Actions
Tools like the Global Dossier provide access to the file histories of related applications, including office actions. This helps in understanding the patent's prosecution history and any challenges faced during the examination process[1].
Public Search Facilities
Resources such as the USPTO Public Search Facility and Patent and Trademark Resource Centers (PTRCs) offer public access to patent and trademark information. These facilities are essential for conducting thorough patent searches and ensuring that the invention is novel and non-obvious[1].
Sequence Listings and Mega Items
For patents involving biological sequences, such as this one, the Publication Site for Issued and Published Sequences (PSIPS) provides access to sequence listings, tables, and other mega items. This ensures that all relevant biological data is available for public review[1].
Conclusion
United States Patent 10,287,586 is a comprehensive patent that covers a range of antisense molecules and methods for treating genetic diseases. The scope of the patent is well-defined by its claims, which specify the structure and use of these molecules. The patent landscape, including international filings and prior art, underscores the novelty and non-obviousness of the invention.
Key Takeaways
- Specific Target Sites: The patent targets specific exons in the dystrophin gene to induce exon skipping.
- Methods of Treatment: The invention includes methods for treating genetic diseases like Duchenne muscular dystrophy.
- Pharmaceutical Compositions: The patent covers pharmaceutical compositions and kits containing the antisense molecules.
- International Protection: The invention is protected through international patents and databases.
- Examination Process: The patent underwent a rigorous examination process, resulting in narrower claims.
FAQs
Q: What is the primary focus of United States Patent 10,287,586?
A: The primary focus is on antisense molecules designed to induce exon skipping in the dystrophin gene for treating genetic diseases like Duchenne muscular dystrophy.
Q: How are the antisense molecules administered?
A: The antisense molecules are administered to patients in a form suitable for therapeutic use, often as part of a pharmaceutical composition.
Q: What are the target exons for exon skipping?
A: The target exons include exons 3, 4, 8, 10, 26, 36, 48, 60, 66, and 68 of the dystrophin gene.
Q: Is the patent protected internationally?
A: Yes, the invention is protected through international patents and databases such as WIPO PATENTSCOPE and EPO esp@cenet.
Q: Where can one find detailed information on the patent's expiration and generic entry?
A: Detailed information on the patent's expiration and potential generic entry can be found on websites like DrugPatentWatch.
Sources
- USPTO - Search for patents - USPTO
- Regulations.gov - Untitled - Regulations.gov
- SSRN - Patent Claims and Patent Scope - Search eLibrary :: SSRN
- Google Patents - US10287586B2 - Antisense molecules and methods for treating pathologies
- DrugPatentWatch - Pharmaceutical drugs covered by patent 10,287,586. Claims ...
